

**Amendments to the Drawings**

Please replace Figures 1C and 1D with the Replacement Drawing Sheets accompanying this submission. The changes made in the Replacement Sheets are fully described in the Remarks Section of this Submission, and are noted on the Annotated Sheets included in the Appendix.

Attachments: Replacement Sheets for Figures 1C (11 sheets) and 1D (14 sheets)  
Annotated Sheet Showing Changes to Figures 1C (11 sheets) and 1D (14 sheets)

Remarks

Status

The application has been placed in condition for allowance, except for formal matters which have to be resolved in order to put the specification into compliance with the sequence listing rules set forth in 37 C.F.R. §§1.821 – 1.825.

Prosecution on the merits is closed in accordance with the practice under *Ex parte Quayle*.

Claims 7, 8, 28 and 33-38 are allowable.

The Office Action mailed from the USPTO on May 5, 2009 indicates that upon Applicant's resolution of the formal matters indicated in the Office Action, the Examiners Amendment, which was attached to the Office Action will be entered into the record, and a Notice of Allowance will subsequently be issued.

Formal Matters Noted in the Office Action

The Office Action indicates that the disclosure of the instant application is rejected because "there are sequences disclosed in the specification and drawings which are not properly identified by sequence identification numbers" (Office Action, page 2). Furthermore, it is noted that the specification lists SEQ ID NOS: which are not currently present in the sequence listing which only contains 156 sequences. The Office Action indicates that Applicants should review the application in its entirety to ensure compliance with the sequence listing rules.

Amendments to the Specification

The above-mentioned amendments are made to insert the required SEQ ID NO identifiers assigned to numerous sequences that are disclosed in the specification, but which were not included in the original sequence listing.

The figure legends for Figures 1A and 1B have been amended to describe the sequences disclosed and the figures and to include SEQ ID NOS:.

The figure legends for Figures 1C and Figure 1D have been amended to indicate that the VL/FR sequences are set forth as consecutive framework segments (i.e., FR1, FR2, FR3 and FR4) and CDR (i.e., CDR1, CDR2 and CDR3) placeholders.

The amendment made on page 26, line 24 to page 27, line 21 of the specification are made to correct sequence discrepancies in SEQ ID NOS 311-337. Namely, the first two residues, "CA," were inserted into the sequences at the N-terminal. Support for said correction may be found in Figure 1D wherein the correct sequences are disclosed. No new matter has been added.

Paper and computer-readable copies of a Substitute Sequence Listing which includes all 443 sequences disclosed in the instant specification have been provided, along with an amendment requesting entry of the substitute sequence listing into the specification. In addition,

the paper and computer readable copies of the Sequence Listing is accompanied by a Statement indicating that the substitute sequence submitted herewith does not include new matter and that the content of the paper and computer-readable listings are the same.

### **Amendments to the Drawings**

#### **Amendments to the Drawings**

##### **Figure 1C**

Replacement Sheets are provided for Figures 1C and 1D. The Figure 1C and 1D Replacement Sheets (11 sheets for Figure 1C and 14 sheets for Figure 1D) are included in the Appendix along with Annotated Sheets Showing Changes.

The first 5 sheets of Figure 1C (which comprises a total of 11 sheets) provide amino acid sequence information for various VL chains of selected anti-VEGF antibodies. As noted on the Annotated Sheets for Figure 1C, the replacement drawing includes a change to SEQ ID NO: 10 (which occurs on sheet 1 of Figure 1C). As noted in the annotated sheet accompanying this submission, this sequence was originally set forth as having an N-terminal "I" residue, however the correct N-terminal residue is "D." The replacement sheet sets forth the correct amino acid for SEQ ID NO: 10. The corrected sheet contains no new matter. Support for the corrected sequence can be found in the Sequence Listing which was filed with the application. No changes were made to the sequences disclosed on sheets 2-7.

The last 4 sheets (sheets 8-11) of Figure 1C provide amino acid sequence information for various VL/FRs of selected anti-VEGF antibodies. As noted above (in the Amendments to the Specification section) the Figure legend has been amended to indicate that the VL/FR sequences are set forth as consecutive framework segments (i.e., FR1, FR2, FR3 and FR4) and CDR (i.e., CDR1, CDR2 and CDR3) placeholders.

The format of last 4 sheets of Figure 1C has been amended to bring the disclosure into compliance with the sequence listing rules by providing each of the framework segments a unique SEQ ID NO:. Therefore, each of the frameworks set forth on sheets 7-11 of Figure 1C comprises 4 consecutive framework segments (i.e., FR1, FR2, FR3, and FR4) with intervening CDR regions occurring at the positions indicated by the placeholders (CDR1, CDR2 and CDR3). The text provided above each of the VL amino acid sequences has been amended to provide a list of SEQ ID NOS: comprising each of the disclosed VL framework sequences. No new matter was added by this amendment. The specification as filed provides support for the recitation of the terms FR1, FR2, FR3 and FR4 on page 64, lines 15-16.

**Figure 1D**

The first 9 sheets of Figure 1D (which comprises a total of 14 sheets) provide amino acid sequence information for various VH chains of selected anti-VEGF antibodies. The replacement sheets for Figure 1D include two amendments made to correct typographical errors. As indicated on page 3 of the annotated sheets, spaces were deleted from the beginning of SEQ ID NO:79 to make the sequence information begin at the left-justified margin. In addition, the format of the term "SEQ ID NO:" on sheet 4 of Figure 1D was corrected for SEQ ID NO: 90. The corrected sheets contain no new matter. No changes were made to sheets 1-2 and 5-12.

The last 2 sheets (sheets 13 and 14) of Figure 1D provide amino acid sequence information for various VH/FRs of selected anti-VEGF antibodies. As noted above the Figure legend has been amended to indicate that the VH/FR sequences are set forth as consecutive framework segments (i.e., FR1, FR2, FR3 and FR4) and CDR (ie., CDR1, CDR2 and CDR3) placeholders. The format of last 4 sheets of Figure 1D has been amended to bring the disclosure into compliance with the sequence listing rules by providing each of the framework sequences a unique SEQ ID NO:. Therefore, each of the frameworks set forth on sheets 13-14 of Figure 1D comprises 4 consecutive framework regions (i.e., FR1, FR2, FR3, and FR4) with intervening CDR regions occurring at the positions indicated by the placeholders (CDR1, CDR2 and CDR3). The text provided above each of the VH sequences has been amended to provide a list of SEQ ID NOS: comprising each of the disclosed VH framework sequences. No new matter was added by this amendment. The specification as filed provides support for the recitation of the terms FR1, FR2, FR3 and FR4 on page 64, lines 15-16.

Summary

For the reasons set forth hereinabove, Applicants believe that the present application is now in condition for allowance. Favorable reconsideration of the application as amended is respectfully requested. Applicants respectfully request that a timely Notice of Allowance be issued for this case.

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorney invites the Examiner to telephone her at the number provided below.

Respectfully submitted,

By   
Patricia Chisholm  
Reg. No. 45,822  
Assistant Counsel

MERCK & CO., INC.  
P.O. Box 2000  
Rahway, New Jersey 07065-0907  
(732) 594-5738

July 2, 2009



# REPLACEMENT SHEETS

ANNOTATED  
SHEETS

ANNOTATED SHEET

USSN 10/723,434

SHEET 1/11

FIGURE 1C

Figure 1C

**Amino Acid Sequences of  $V_L$  of selected Anti-VEGF Antibodies**

SEQ ID NO:1  
DIQWTQSPSSLSAVGDRVTITCSASQDISNYLNWYQQKPGKAPVKLIYFTSSLHSGVPNSRFSGSGSGTDFTLTISLQPEDFATYYCQQYSTVPWTFGQGTKVEIK

SEQ ID NO:2  
DIELTQSPSSLSVSAGDRVTISCSASSQDISNYLNWYQQKPGKAPRVLIIYFTSSLHSGVPYRFSGSGSGTDFTLTISLQPEDVAVYYCQQYSTVPWTFGQGTKVEIK

SEQ ID NO:3  
DIELTQSPSSLSVTPGERATITCSASQDISNYLNWYQQKPGQAPQLLIIYFTSSLHSGVPDRFSGSGSGTDFTLTISRLQaedaIAYYCQQYSTVPWTFGQGTKVEIK

SEQ ID NO:4  
DIELTQSPSSLSVTPGERATITCSASQDISNYLNWYQQKPGQAPQLLIIYFTSSLHSGVPDRFSGSGSGTDFTLTISRLQaedaDVAVYYCQQYSTVPWTFGQGTKVEIK

SEQ ID NO:5  
DIELTQSPSSLSASLGERVTISCSASSQDISNYLNWYQQKPGKAPHLIIFYFTSSLHSGVPYRFSGSGSGTDFTLTISLQaedaFAAYYCQQYSTVPWTFGQGTKVEIK

SEQ ID NO:6  
DIVMTQSPSSLSATPGERTVTITCSASQDISNYLNWYQQKPGQAPRVLIIYFTSSLHSGVPDRFSGSGSGTDFTLTISLQPEDVAVYYCQQYSTVPWTFGQGTKVEIK

SEQ ID NO:7  
DIVMTQSPSSLSATPGERTVTISCSASQDISNYLNWYQQKPGKAPSLLVYFTSSLHSGVPNSRFSGSGSGTDFTLTISRLQaedaIAYYCQQYSTVPWTFGQGTKVEIK

SEQ ID NO:8  
DIVLTQSPSSLSATPGDRVTITCSASQDISNYLNWYQQKPGQAPQLLIIYFTSSLHSGVPNSRFSGSGSGTDFTLTISLQaedaDVAIYYCQQYSTVPWTFGQGTKVEIK

SEQ ID NO:9  
DIVLTQSPSSLSATPGERTATITCSASQDISNYLNWYQQKPGKAPHLIIFYFTSSLHSGVPYRFSGSGSGTDFTLTISLQaedaFAIAYYCQQYSTVPWTFGQGTKVEIK

SEQ ID NO:10  
| DIELMTQSPSSLSATPGDRVTITCSASQDISNYLNWYQQKPGKAPRVLIIYFTSSLHSGVPYRFSGSGSGTDFTLTISRLQPEDDVAIYYCQQYSTVPWTFGQGTKVEIK

SEQ ID NO:11  
DIELMTQSPSSLSVTPGDRVTITCSASQDISNYLNWYQQKPGKAPHLIIFYFTSSLHSGVPDRFSGSGSGTDFTLTISRLQPEDFATYYCQQYSTVPWTFGQGTKVEIK

SEQ ID NO:12  
DIELTQSPSSLSATLGERVTISCSASSQDISNYLNWYQQKPGKAPHLIIFYFTSSLHSGVPNSRFSGSGSGTDFTLTISRLQaedaDVAIYYCQQYSTVPWTFGQGTKVEIK

→ **Inserted N-terminal "D" residue**

ANNOTATED SHEET

USSN 10/723,434

SHEET 2/11

FIGURE 1C

Figure 1C-cont.

SEQ ID NO:13

DIVMTQSPSSLSASPGERATISCKASSQSIGTYLAWYQQKPGQAPRVLIIYFTSSLHSGVPDRFSGSGSGTDFTLTISSLQAEDFAVYYCQQYSTVPWTFGGTKEIK

SEQ ID NO:14

DIVLTQSPSSLSASAGDRTTISCSASQDISNVLNMYQQKPGQAPRVLIIYFTSSLHSGVPDRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGGTKEIK

SEQ ID NO:15

DIVMTQSPSSLSASPGERATISCNASSQSIGTYLAWYQQKPGQAPRVLIIYGAASNLAQVPGRFSGSGSGTDFTLTISSLQPEDFAVYYCQQYNASKPWTFFGGTKEIK

SEQ ID NO:16

DIVMTQSPSSLSASPGERATISCRASSQSISSYLAWYQQKPGQAPRVLIIYGAASNLAQVPGRFSGSGSGTDFTLTISSLQPEDFAVYYCQQYSSSPWTFFGGTKEIK

SEQ ID NO:17

DIVMTQSPSSLSASPGERATITCHASSQSIGTYLAWYQQKPGQAPRVLIIYGAASNLAQVPGRFSGSGSGTDFTLTISSLQPEDFAVYYCQQYSTVPWTFGGTKEIK

SEQ ID NO:18

DIVMTQSPSSLSASPGERATITCKASSQSIGTYLAWYQQKPGQAPRVLIIYDAASNLAQVPGRFSGSGSGTDFTLTISSLQPEDFAVYYCQQYSTVPWTFGGTKEIK

SEQ ID NO:19

DIVMTQSPSSLSASPGERATITCKASSQSIGSYLAWYQQKPGQAPRVLIIYDAASNLAQVPGRFSGSGSGTDFTLTISSLQPEDFAVYYCQQYSSSTPYTFGGTKEIK

SEQ ID NO:20

DIVMTQSPSSLSASPGERATISCKASSQSIGSYLAWYQQKPGQAPSVLIIYASNLASGVPNRFSGSRSGTDFTLTISSLQPEDFAVYYCQQYSSGPWTFFGGTKEIK

SEQ ID NO:21

DIVMTQSPSSLSASPGERATITCNASSQSISSYLAWYQQKPGQAPRVLIIYGAASNLAQVPGRFSGSGSGTDFTLTISSLQPEDFAVYYCQQYNASKPWTFFGGTKEIK

SEQ ID NO:22

DIVMTQSPSSLSASPGERATISCKASSQSIGSYLAWYQQKPGQAPRVLIIYASNLASGVPSRFSGRSGTDFTLTISSLQPEDFAVYYCQQYNASKPWTFFGGTKEIK

SEQ ID NO:23

DIVMTQSPSSLSASPGERATISCKASSQSIGTYLAWYQQKPGQAPRVLIIYDAASNLAQVPGRFSGSGSGTDFTLTISSLQPEDFAVYYCQQYSTVPWTFGGTKEIK

SEQ ID NO:24

DIVMTQSPSSLSASPGERATISCKASSQSIGTYLAWYQQKPGQAPRVLIIYASNLASGVPNRFSGSGSGTDFTLTISSLQPEDFAVYYCQQYSSSTPYTFGGTKEIK

No changes

Figure 1C-cont.

SEQ ID NO : 25  
 DIVMTQSPSTLISASPGERATITCCHASQSISSTYLAWYQQKPGQAPNVLIYAGASNLLASGVVPDRFGSGSGTDFLTISLQPEDFAVYYCQQYNSTPWTFFGGTKEIK

SEQ ID NO : 26  
 DIVMTQSPSTLISASPGERATITCCHASQSISSTYLAWYQQKPGQAPRVLIIYAGASNLLASGVPNRFSGSGSGTDFLTISLQPEDFAVYYCQQYNSAPWTFFGGTKEIK

SEQ ID NO : 27  
 DIVMTQSPSTLISASPGERATITCCKASQSISSTYLAWYQQKPGQAPQVLIIYDASNLASGVPNRFSGSGSGTDFLTISLQPEDFAVYYCQQYNSTPWTFFGGTKEIK

SEQ ID NO : 28  
 DIVMTQSPSTLISASPGERATITCNAQSISGTYLAWYQQKPGQAPNLIIYDASNLASGVPSRFSRGSGTDFLTISLQPEDFAVYYCQQYSSTPWTFFGGTKEIK

SEQ ID NO : 29  
 DIVMTQSPSTLISASPGERATITCNAQSISGTYLAWYQQKPGQAPNLIIYDASNLASGVPGRFSGSGSGTDFLTISLQPEDFAVYYCQQYSSTPWTFFGGTKEIK

SEQ ID NO : 30  
 DIVMTQSPSTLISASPGERATITCNAQSISGTYLAWYQQKPGQAPNVLIYDASNLASGVPSRFSRGSGTDFLTISLQPEDFAVYYCQQYSSAPWTFFGGTKEIK

SEQ ID NO : 31  
 DIVMTQSPSTLISASPGERATITCNAQSISSTYLAWYQQKPGQAPRVLIIYAGASNLLASGVPSRFSRGSGSGTDFLTISLQPEDFAVYYCQQYNSTPWTFFGGTKEIK

SEQ ID NO : 32  
 DIVMTQSPSTLISASPGERATITCQASQSISSTYLAWYQQKPGQAPKVLIIYDASNLASGVPGRFSGSGSGTDFLTISLQPEDFAVYYCQQYNSTPWTFFGGTKEIK

SEQ ID NO : 33  
 DIVMTQSPSTLISASPGERATITCRAQSQSISSTYLAWYQQKPGQAPRLLIIYASNLASGVPNRFSGSGSGTDFLTISLQAEDDFAVYYCQQYXSTPWTFFGGTKEIK

SEQ ID NO : 34  
 DIVMTQSPSTLISASPGERATITCSCASQSISGTYLAWYQQKPGQAPSVLIIYAGASNLLASGVPGRFSGSGSGTDFLTISLQPEDFAVYYCQQYNSAPWTFFGGTKEIK

SEQ ID NO : 35  
 DIVMTQSPSTLISASPGERATITCSCASQSISSTYLAWYQQKPGQAPQVLIIYASNLASGVPSRFSRGSGTDFLTISLQPEDFAVYYCQQYXSTPWTFFGGTKEIK

SEQ ID NO : 36  
 AIRMTQSPSSVVASVGDVTIACRASQAIRNDLWYQQKPGTAKPLIYGATTIQLSGVPSRFSRGSGSGTDFLTISLQPEDFAVYYCQQSSSTPWTFFGGTKEIK

SEQ ID NO : 37  
 DIVMTQTPSSLISASVGDVTIICRASRDIRNDLWYQQKPGKAPELLIIYAASSLQSGVPSRFSRGSGSGTDFLTISLQPEDFAVYYCQQSSYXSTPWTFFGGTKEIK

No changes

Figure 1C-cont.

SEQ ID NO : 38  
EIVLTQSPSSLSASIGDRVAILTCRASRDITTDLAWYQQIPGKAPKLLIYAASRLQSGVPSRFSGGSGTDFLTISLQPEDFAAYCQSYSTPWTFFGQGTTKVDIKSEQ ID NO : 39  
EIVLTQSPSSLSASVGDRRITITCRASRDIRDDLAWYQQKPGKAPKVLIIYAASSLQSGVPSRFSGGSGTDFLTISLQPEDFAATYYCQSYSTPWTFFGQGTTKLEIKSEQ ID NO : 40  
EIVLTQSPSSLSASVGDRVTITCRASQISTYINWYQQKPGKAPKLLIYAASSLQSGVTSRFSGGSGTDFLTISLQPEDFAATYYCQSYSTPWTFFGQGTTKVEIKSEQ ID NO : 41  
EIVMTQSPSSLSASVGDRVTITCRASQAIYDYLAWYQQKPGKAPNLIIYAASRLQSGVPSRFSGGSGTDFLTISLQPEDFAATYYCQSYSTPWTFFGQGTTKVDIKSEQ ID NO : 42  
EIVMTQSPSSLSASVGDRVTITCRASSDIRKDLAWYQQKPGKAPKVLIIYAASLTLQSGVPSRFSGGSGTDFLTISLQPEDFAATYYCQSYSTPWTFFGQGTTKLEIKSEQ ID NO : 43  
EIVMTQSPSSLSASVGDRVTITCRASSQISTYINWYQQKPGKAPKLLIYAASSLQSGVTSRFSGGSGTDFLTISLQPEDFAATYYCQSYSTPWTFFGQGTTKVEIKSEQ ID NO : 44  
EIVMTQSPSSLSASVGDTVTIACRASRDIRNDLAWYQQKPGKAPKLLIYAASRLQSGVPSRFSGTSGSGTDFALTISLQPEDSASYCQSYTIPWTFFGQGTTKLEIKSEQ ID NO : 45  
EIVMTQSPSSLSASVGDTITISCRSSQPTNDLAWYQQKPGKAPNLIIYAASRLQGGVPSRFSGGSGTDFLTISLQPEDFAATYYCQSYSTPWTFFGQGTTKVEIKSEQ ID NO : 46  
LPVLTQPPSAASGTPGQRTTISCSGSTSNIIGSNPVDNWWYQQLPGTAPKLLIYNNQRPSGVPDFRSGSKSGTSASLAIISGLLSEDEADYYCAAWDSLNGYVFGTGTQL  
TVLSEQ ID NO : 47  
LPVLTQPPSAASGTPGQRTTISCSGSTSNIIGSNVWYQQLPGTAPKVLMYNNQRPSGVPDFRSGSKSGTSASLAIISGLQSEDEADYYCAAWDSLNGYVFGTGTQL  
TVLSEQ ID NO : 48  
NPMLTQPPSTSCTPGQRTTISCSGSTSNIIGSNVWYQQLPGTAPKVLMYNNQRPSGVPERSGSKSGTSASLAIISGLQSEDEADYYCAAWDSLNGYVFGTGTQL  
TVLSEQ ID NO : 49  
QAVLTQPPSAASGTPGQSYTISCSGTTTSNIGSNVWYQQLPGTAPKVLIIYGNDRPSGVPDFRSGSKSGTSASLAIISGLQSEDEADYYCAAWDSLNGYVFGTGTQL  
TVL

No. Changes

Figure 1C-cont.

SEQ ID NO: 50  
QPVLTQPPSAATPGQRTVTISCGSSSNIGSNPVPNWWYQQLPGTAPKVL<sup>I</sup>YNNQRPSPGVPDFSGSKSGTSASLAI<sup>S</sup>GLQSEDEADYYCAAWDDSLSGYVFGTGTKL  
TVL

SEQ ID NO: 51  
QPVLTQPPSAATPGQRTVTISCGSSSNIGSNPVPNWWYQQLPGTAPKVL<sup>I</sup>YNNQRPSPGVPDFSGSKSGTSASLAI<sup>S</sup>GLQSEDEADYYCAATWDDSLNGYVFGTGTQL  
TVL

SEQ ID NO: 52  
QPVLTQPPSTSGTPGQRTVTISCGSSSNIGSNPVPNWWYQQLPGTAPKVL<sup>I</sup>YNNQRPSPGVPERFSGSKSGTSASLAI<sup>S</sup>GLQSEDEADYYCAAWDDSLSGYVFGTGTKL  
TVL

SEQ ID NO: 53  
QPVLTQPPSAATPGQRTVTISCGSNSNIGSNPVPNWWYQQLPGTAPKVL<sup>I</sup>YNNQRPSPGVPDFSGSKSGTSASLAI<sup>S</sup>GLQSEDEADYYCAAWDDSLNGYVFGTGTKL  
TVL

SEQ ID NO: 54  
QSALTQPPSVSGAPGQRTVTISCTGRSSNIGAGHDVHWWYQQLPGTAPKLL<sup>I</sup>YANDQRPSGVPDFSDSKSGTSASLGISGLRSEDEADYFCATWDDSLHGYVFGTGTKL  
TVL

SEQ ID NO: 284  
DQMTQTSSLSAATLGDRVIIISCSAATQDISNYLNWYQQKPDGTVKVL<sup>I</sup>YFTSSLHSGVPSRFSGSGSGTDYSLTISNLEPEDIATYYCQQYSTVPWTFGGGTKLEIK

No. Changes

Figure 1C-cont.

**Amino Acid Sequences of V<sub>l</sub>/CDR1 of Selected Anti-VEGF Antibodies**

SEQ ID NO:164	NASQSIGTYLA
SEQ ID NO:165	KASQSIGTYLA
SEQ ID NO:166	HASQSISSTYLA
SEQ ID NO:167	SASQSISSTYLA
SEQ ID NO:168	RASQSISSTYLA
SEQ ID NO:169	KASQSIGSYLA
SEQ ID NO:170	HASQSISSTYLA
SEQ ID NO:171	RASQSISSTYLA
SEQ ID NO:172	NASQSIGSYLA
SEQ ID NO:173	SASQSIGTYLA
SEQ ID NO:174	KASQSISSTYLA
SEQ ID NO:175	NASQSISSTYLA
SEQ ID NO:176	HASQSIGTYLA
SEQ ID NO:177	QASQSISSTYLA
SEQ ID NO:178	RASQSISSTYIN
SEQ ID NO:179	RASRDIRNDLA
SEQ ID NO:180	RASRDITTDLA
SEQ ID NO:181	RASQDIRKDLA
SEQ ID NO:182	RASQAIRNDLT
SEQ ID NO:183	RASQAIYDYL
SEQ ID NO:184	RSSQPIITNDLA
SEQ ID NO:185	RASRDIRDILDA
SEQ ID NO:186	SGSSSNVGRNTVN
SEQ ID NO:187	SGSTSNIIGSNPVN
SEQ ID NO:188	TGRSSSNIGAGHDVH
SEQ ID NO:189	SGSNSNIGSNNNVY
SEQ ID NO:190	SGSYSNIGSNNAVN
SEQ ID NO:191	SGTTTSNIGGSNSVN
SEQ ID NO:192	SGSSSNIGGSNSVT
SEQ ID NO:193	SGSTSNIIGGSNSVT
SEQ ID NO:194	SGSSSNIGSNPVN

No changes

Figure 1C-cont.

**Amino Acid Sequences of V<sub>L</sub>/CDR2 of Selected Anti-VEGF Antibodies**

SEQ	ID	NO:195	GASNLAS
SEQ	ID	NO:196	DASNLAS
SEQ	ID	NO:197	SASNLAS
SEQ	ID	NO:204	AASNLAS
SEQ	ID	NO:198	AASSLQS
SEQ	ID	NO:199	AASRLQS
SEQ	ID	NO:200	AASTLQS
SEQ	ID	NO:201	GATTLQS
SEQ	ID	NO:202	AASRLQG
SEQ	ID	NO:203	GNDERPS
SEQ	ID	NO:205	ANDQRPSS
SEQ	ID	NO:206	GNNQRPS
SEQ	ID	NO:207	TNNQRPS
SEQ	ID	NO:208	GNDQRPSS
SEQ	ID	NO:209	SNNQRPS

**Amino Acid Sequences of V<sub>L</sub>/CDR3 of Selected Anti-VEGF Antibodies**

SEQ	ID	NO:210	QQYNSKPKWTT
SEQ	ID	NO:211	QQYSSTTPVTT
SEQ	ID	NO:212	QQYNNSTPWT
SEQ	ID	NO:213	QQYYSTPWT
SEQ	ID	NO:214	QQYNSAPWT
SEQ	ID	NO:215	QQYSSSSPWT
SEQ	ID	NO:216	QQYYSGPWT
SEQ	ID	NO:217	QQYSSTPWT
SEQ	ID	NO:218	QQYSAPWT
SEQ	ID	NO:219	QQSYSTPWT
SEQ	ID	NO:220	QQSYSPPWT
SEQ	ID	NO:221	QQSYTILPWT
SEQ	ID	NO:222	QQSSTTPWT
SEQ	ID	NO:223	ATWDDDSLNGTV
SEQ	ID	NO:224	ASWDDDSLGTGV
SEQ	ID	NO:225	ATWDDDSLHGTV
SEQ	ID	NO:226	GAWDDDSLNGVV
SEQ	ID	NO:227	AAWDDDSLNGVV
SEQ	ID	NO:228	AAWDDDSLSGVV

No. Changes

Figure 1C-cont.

**Amino Acid Sequences of V<sub>L</sub>/FRs of Selected Anti-VEGF Antibodies**

SEQ ID NOS <u>229</u> and <u>351-353</u> DIVMTQSPSSLSASPGERATISC/CDR1/WYQQKPGQAPVLIY/CDR2/GVPGRFSGSGSGTDFLTISLQPEDFAVYYC/CDR3/FGGGTKEIK [Deleted: : ]
SEQ ID NOS <u>230</u> , <u>354-355</u> and <u>353</u> DIVMTQSPSTLSASPGERATITC/CDR1/WYQQKPGQAPRVLIIY/CDR2/GVPNRFSGSSRGTDFTLTISLQPEDFAVYYC/CDR3/FGGGTKEIK [Deleted: : ]
SEQ ID NOS <u>231</u> , <u>356-357</u> and <u>353</u> DIVMTQSPSTLSASPGERATITC/CDR1/WYQQKPGQAPVLIY/CDR2/GVPDRFSGSSRGTDFTLTISLQPEDFAVYYC/CDR3/FGGGTKEIK [Deleted: : ]
SEQ ID NOS <u>232</u> , <u>351</u> , <u>355</u> and <u>353</u> DIVMTQSPSTLSASPGERATITC/CDR1/WYQQKPGQAPRLLIIY/CDR2/GVPNRFSGSSRGTDFTLTISLQPEDFAVYYC/CDR3/FGGGTKEIK [Deleted: : ]
SEQ ID NOS <u>233</u> , <u>358</u> , <u>355</u> and <u>353</u> DIVMTQSPSTLSASPGERATITC/CDR1/WYQQKPGQAPRLLIIY/CDR2/GVPNRFSGSSRGTDFTLTISLQPEDFAVYYC/CDR3/FGGGTKEIK [Deleted: : ]
SEQ ID NOS <u>234</u> , <u>354</u> , <u>359</u> and <u>353</u> DIVMTQSPSTLSASPGERATISC/CDR1/WYQQKPGQAPRVLIIY/CDR2/GVPSRFSGSSRGTDFTLTISLQPEDFAVYYC/CDR3/FGGGTKEIK [Deleted: : ]
SEQ ID NOS <u>235</u> , <u>354</u> , <u>360</u> and <u>353</u> DIVMTQSPSTLSASPGERATISC/CDR1/WYQQKPGQAPRVLIIY/CDR2/GVPNRFSGSSRGTDFTLTISLQPEDFAVYYC/CDR3/FGGGTKEIK [Deleted: : ]
SEQ ID NOS <u>236</u> , <u>351</u> , <u>360</u> and <u>353</u> DIVMTQSPSTLSASPGERATITC/CDR1/WYQQKPGQAPRVLIIY/CDR2/GVPNRFSGSSRGTDFTLTISLQPEDFAVYYC/CDR3/FGGGTKEIK [Deleted: : ]
SEQ ID NOS <u>237</u> , <u>361</u> , <u>359</u> and <u>362</u> DIVMTQSPSTLSASPGERATITC/CDR1/WYQQKPGQAPRVLIIY/CDR2/GVPSRFSGSSRGTDFTLTISLQPEDFAVYYC/CDR3/FGGGTKEIK [Deleted: : ]
SEQ ID NOS <u>238</u> , <u>363</u> , <u>355</u> and <u>353</u> DIVMTQSPSTLSASPGERATITC/CDR1/WYQQKPGQAPSVLIIY/CDR2/GVPNRFSGSSRGTDFTLTISLQPEDFAVYYC/CDR3/FGGGTKEIK [Deleted: : ]
SEQ ID NOS <u>239</u> , <u>363-364</u> and <u>353</u> DIVMTQSPSTLSASPGERATITC/CDR1/WYQQKPGQAPSVLIIY/CDR2/GVPGRFSGSGSGTDFLTISLQPEDFAVYYC/CDR3/FGGGTKEIK [Deleted: : ]
SEQ ID NOS <u>240</u> and <u>351-353</u> DIVMTQSPSTLSASPGERATITC/CDR1/WYQQKPGQAPVLIY/CDR2/GVPGRFSGSGSGTDFLTISLQPEDFAVYYC/CDR3/FGGGTKEIK [Deleted: : ]

The Sequence Identifiers Listed Above in Blue Text were added to each of the Sequence Descriptions, and ";"'s were removed after the term "SEQ ID NOS".

Figure 1C-cont.

SEQ ID NQS 241, 351, 360 and 353 DIVMTQSPSTLSASPGERATITC/CDR1/WYQQKPGQAPQVLIV/CDR2/GVPNRFSGSGSGTDFLTISLQPEDFAVYYC/CDR3/FGGGTKEIK	Deleted: : [REDACTED]
SEQ ID NQS 242, 354, 360 and 353 DIVMTQSPSTLSASPGERATITC/CDR1/WYQQKPGQAPRVLIV/CDR2/GVPNRFSGSGSGTDFLTISLQPEDFAVYYC/CDR3/FGGGTKEIK	Deleted: : [REDACTED]
SEQ ID NQS 243, 354, 365 and 353 DIVMTQSPSTLSASPGERATITC/CDR1/WYQQKPGQAPRVLIV/CDR2/GVPNSRFSGSGSGTDFLTISLQPEDFAVYYC/CDR3/FGGGTKEIK	Deleted: : [REDACTED]
SEQ ID NQS 244, 366-367 and 353 DIVMTQSPSTLSASPGERATITC/CDR1/WYQQKPGQAPNLLIV/CDR2/GVPGRFSGSRSGTDFLTISLQPEDFAVYYC/CDR3/FGGGTKEIK	Deleted: : [REDACTED]
SEQ ID NQS 245, 368-369 and 353 DIVMTQSPSTLSASPGERATITC/CDR1/WYQQKPGQAPRVLIV/CDR2/GVPNRFSGSRSGTDFLTISLQPEDFAVYYC/CDR3/FGGGTKEIK	Deleted: : [REDACTED]
SEQ ID NQS 246, 354-355 and 370 DIVMTQSPSTLSASPGERATITC/CDR1/WYQQKPGQAPRVLIV/CDR2/GVPNRFSGSRSGTDFLTISLQPEDFAVYYC/CDR3/FGGGTKEIK	Deleted: : [REDACTED]
SEQ ID NQS 247, 361 and 352-353 DIVMTQSPSTLSASPGERATITC/CDR1/WYQQKPGQAPKVLIV/CDR2/GVPGRFSGSGSGTDFLTISLQPEDFAVYYC/CDR3/FGGGTKEIK	Deleted: : [REDACTED]
SEQ ID NQS 248, 356, 359 and 353 DIVMTQSPSTLSASPGERATITC/CDR1/WYQQKPGQAPNVLIV/CDR2/GVPNSRFSGSRSGTDFLTISLQPEDFAVYYC/CDR3/FGGGTKEIK	Deleted: : [REDACTED]
SEQ ID NQS 249, 361, 360 and 353 DIVMTQSPSTLSASPGERATITC/CDR1/WYQQKPGQAPKVLIV/CDR2/GVPNRFSGSGSGTDFLTISLQPEDFAVYYC/CDR3/FGGGTKEIK	Deleted: : [REDACTED]
SEQ ID NQS 250 and 371-373 EIVLTQSPSTLSASVGDRRTITC/CDR1/WYQQKPGKAPKLLIV/CDR2/GVTSRFSGSGSGTDFLTIRSLQPEDFATYYC/CDR3/FGGGTKEIK	Deleted: : [REDACTED]
SEQ ID NQS 251 and 374-376 EIVLTQSPSTLSASVGDRRTITC/CDR1/WYQQKPGKAPELLIV/CDR2/GVPSRFSGSGSGTDFLTISLQPEDFATYYC/CDR3/FGGGTKEIK	Deleted: : [REDACTED]
SEQ ID NQS 252, 377-378 and 376 EIVLTQSPSTLSASIGDRVATITC/CDR1/WYQQIPGKAPKLLIV/CDR2/GVPSRFSGSGSGTDFLTISLQPEDFATYYC/CDR3/FGGGTKEIK	Deleted: : [REDACTED]
SEQ ID NQS 253 and 371-373 EIVLTQSPSTLSASVGDRRTITC/CDR1/WYQQKPGKAPKLLIV/CDR2/GVTSRFSGSGSGTDFLTIRSLQPEDFATYYC/CDR3/FGGGTKEIK	Deleted: : [REDACTED]

[Same Annotation as for sheet 8] The sequence Identifiers Listed Above in Blue Text were added to each of the Sequence Descriptions and ":"'s were removed after the term "SEQ ID NQS,"

Figure 1C-cont.

SEQ ID NOS <u>254</u> , <u>379</u> , <u>375</u> and <u>380</u> EIVMTQSPSSLSASVGDRVITTC/CDR1/WYQQKPGTAPKVLIIY/CDR2/GVPSRFSGSGSGTDFLTITISSLQPEDFATYYC/CDR3/FGQGTKLEIK	Deleted: : [REDACTED]
SEQ ID NOS <u>255</u> , <u>371</u> , <u>381</u> and <u>380</u> EIVMTQSPSSLSASVGDRVITTC/CDR1/WYQQKPGTAPKLLIIY/CDR2/GVPSRFSGSGSGTDFLTITISSLQPEDSASYC/CDR3/FGQGTKLEIK	Deleted: : [REDACTED]
SEQ ID NOS <u>256</u> , <u>382</u> and <u>375-376</u> AIRMTQSPSSVSASVGDRVITTC/CDR1/WYQQKPGTAPKLLIIY/CDR2/GVPSRFSGSGSGTDFLTITISSLQPEDFATYYC/CDR3/FGQGTKVDIK	Deleted: : [REDACTED]
SEQ ID NOS <u>257</u> , <u>383</u> and <u>375-376</u> EIVMTQSPSSLSASVGDRVITTC/CDR1/WIQQKPGKAPNLLIIY/CDR2/GVPSRFSGSGSGTDFLTITISSLQPEDFATYYC/CDR3/FGQGTKVDIK	Deleted: : [REDACTED]
SEQ ID NOS <u>258</u> , <u>383</u> , <u>375</u> and <u>373</u> ETTLTQSPSSLSASVGDTITISC/CDR1/WYQQKPGKAPNLLIIY/CDR2/GVPSRFSGSGSGTDFLTITISSLQPEDFATYYC/CDR3/FGQGTKVEIK	Deleted: : [REDACTED]
SEQ ID NOS <u>259</u> , <u>384</u> , <u>375</u> and <u>380</u> EIVLTQSPSSLSASVGDRITITC/CDR1/WYQQKPGKAPKVLIIY/CDR2/GVPSRFSGSGSGTDFLTITISSLQPEDFATYYC/CDR3/FGQGTKLEIK	Deleted: : [REDACTED]
SEQ ID NOS <u>260</u> , <u>385</u> , <u>375</u> and <u>373</u> DQLTQSPSSLSASAGDRVTISC/CDR1/WYQQKPGKAPQLLIIY/CDR2/GVPSRFSGSGSGTDFLTITISSLQPEDFATYYC/CDR3/FGQGTKVEIK	Deleted: : [REDACTED]
SEQ ID NOS <u>261</u> and <u>386-388</u> QPVLTOPPSASGTPGQRVTTISC/CDR1/WYQQLPGTAPKLLIIY/CDR2/GVPDRFSGSKSGTSASLAIISGLQSEDEADYYC/CDR3/FGTGTQLTVL	Deleted: : [REDACTED]
SEQ ID NOS <u>262</u> , <u>389-390</u> and <u>388</u> LPVLTOPPSASGTPGQRVTTISC/CDR1/WYQQLPGTAPKLLIIY/CDR2/GVPDRLSGSKSGTSASLAIISGLQSEDEADYYC/CDR3/FGTGTQLTVL	Deleted: : [REDACTED]
SEQ ID NOS <u>263</u> , <u>389</u> and <u>391-392</u> QSLALTQPPSVSGAPGQRVTTISC/CDR1/WYQQLPGTAPKLLIIY/CDR2/GVPDRFSDSKSGTSASLIGSGLRSEDEADYFC/CDR3/FGTGTQLTVL	Deleted: : [REDACTED]
SEQ ID NOS <u>264</u> , <u>393</u> , <u>387</u> and <u>394</u> QSVLTQPPSVSGTPGQRVTTISC/CDR1/WYQQLPGTAPKVLIIY/CDR2/GVPDRFSGSKSGTSASLAIISGLQSEDEADYYC/CDR3/FGTGTQLTVL	Deleted: : [REDACTED]
SEQ ID NOS <u>265</u> , <u>395-396</u> and <u>394</u> LPVLTOPPSASGTPGQRVTTISC/CDR1/WYQQLPGAAPKVLIIY/CDR2/GVPDRFSGSKSGTSASLAIISGLQSEDEADYYC/CDR3/FGTGTQLTVL	Deleted: : [REDACTED]
SEQ ID NOS <u>266</u> and <u>397-399</u> QAVLTQPPSVSGTPGQSVTTISC/CDR1/WYQQLPGTAPKVLIIY/CDR2/GVPDRFSGSSRSATSASLAIISGLQSEDEADYYC/CDR3/FGTGTQLTVL	Deleted: : [REDACTED]

[ same annotations as for sheet 8] The Sequence Identifiers Listed Above in Bla Text were added to each of the Sequence Descriptions, and ":"'s were removed after the term "SEQ ID No 5,"

Figure 1C-cont.

SEQ ID NQS 267, 400-401 and 394  
QPVLTQPPSTSGTPGQRVTISC/CDR1/WYQQLPGTAPKVLMY/CDR2/GVPERFSGSKSGTSASLAISGLQSEDEADYYC/CDR3/FGTGTLKLTVL  
Deleted: : [ ]

SEQ ID NQS 268, 400-401 and 394  
NFMLTQPPSTSGTPGQRVTISC/CDR1/WYQQLPGTAPKVLMY/CDR2/GVPERFSGSKSGTSASLAISGLQSEDEADYYC/CDR3/FGTGTLKLTVL  
Deleted: : [ ]

SEQ ID NQS 269, 397, 387 and 394  
QPVLTQPPSASATPGQRVTISC/CDR1/WYQQLPGTAPKVLITY/CDR2/GVPDRFSGSKSGTSASLAISGLQSEDEADYYC/CDR3/FGTGTLKLTVL  
Deleted: : [ ]

[Same annotation as for Sheet 8] The Sequence Descriptions listed Above in Blue Text were added to each of the Sequence Descriptions, and "as" were removed after the term "SEQ ID Nos."

Figure 1D

Amino Acid Sequences of  $V_h$  of Selected Anti-VEGF Antibodies

SEQ ID NO : 55  
 EVQLVQSGGGVYQPGGSLRLSCAASGYTFTNYGMNNWIRQAPGKGLEWVGWINTYTGEPPTYAADFKRRTFTSLDTSKSTAYLQMNLSRAEDTAVYCAKYPHYYGSSH  
 WYFDWNGQGTTLVTVSS

SEQ ID NO : 56  
 EVQLVQSGGGVYQPGGSLRLSCAASGYDFTHYGMNNWIRQAPGKGLEWVGWINTYTGEPPTYAADFKRRTFTSLDTSKSTAYLQMNLSRAEDTAVYCAKYPHYYGSSH  
 WYFDWNGQGTTLVTVSS

SEQ ID NO : 57  
 EGQLVQSGGGVYQPGGSLRLSCAASGYTFTNYGMNNWIRQAPGKGLEWVGWINTYTGEPPTYAADFKRRTFTSLDTSKNTAYLQMNLSRAEDTAVYCAKYPHYYGSSH  
 WYFDWNGQGTTLVTVSS

SEQ ID NO : 58  
 EVQLVQSGGGVYQPGGSLRLSCAASGYTFTNYGMNNWIRQAPGKGLEWVGWINTYTGEPPTYAADFKRRTFTSLDN SKSQAYLOMNLSRAEDTAVYCAKYPHYYGSSH  
 WYFDWNGQGTTLVTVSS

SEQ ID NO : 59  
 EVQLVQSGGGVYQPGGSLRLSCAASGYTFTNYGMNNWIRQAPGKGLEWVGWINTYTGEPPTYAADFKRRTFTSLDTSKNTAYLQMNLSRAEDTAVYCAKYPHYYGSSH  
 WYFDWNGQGTTLVTVSS

SEQ ID NO : 60  
 EVQLVQSGGGVYQPGGSLRLRCAAASGYTFTNYGMNNWIRQAPGKGLEWVGWINTYTGEPPTYAADFKRRTFTSLDTSKSTAYLQLNLSRAEDTAVYCAKYPHYYGSSH  
 WYFDWNGQGTTLVTVSS

SEQ ID NO : 61  
 EVQLVQSGGGVYQPGGSLRLSCAASGFDFFTNYGMNNWIRQAPGKGLEWVGWINTYTGEPPTYAADFKRRTFTSLDTSKSTAYLQLNLSRAEDTAVYCAKYPHYYGSSH  
 WYFDWNGQGTTLVTVSS

SEQ ID NO : 62  
 EVQLVQSGGGVYQPGGSLRLSCAASGYVALDHFGLNWIRQAPGKGLEWVGWINTYTGEPPTYAADFKRRTFTSLDTSKSTAYLQLNLSRAEDTAVYCAKYPHYYGSSH  
 WYFDWNGQGTTLVTVSS

SEQ ID NO : 63  
 EVQLVQSGGGVYQPGGSLRLSCAASGYDFNYGINWVRQAPGKGLEWVGWINTYTGEPPTYAHEFTRRTFTSLDTSKSTAYLQLNLSRAEDTAVYCAKYPHYYGSSH  
 WYFDWNGQGTTLVTVSS

No changes

Figure 1D-cont.

SEQ ID NO : 64  
EVQLVQSGGGVVQPGGSLRLSCAASGGYSLDHYGMNWRQAPGKGLEWVGWINTYTGEPTYAADEFKRRVTFSLDTSKSTAYLQLNSLRAEDTAVYCAKYPHYGSSH  
WYFDVWQGGTLVTVSS

SEQ ID NO : 65  
EVQLVQSGGGVVQPGGSLRLSCAASGGYTFTNYGMNNWRQAPGKGLEWVGWINTYTGEPTYAADEFKRRVTFSLDTSKNTAYLQLNSLRAEDTAVYCAKYPHYGSSH  
WYFDVWQGGTLVTVSS

SEQ ID NO : 66  
EVQLVQSGGGVVQPGGSLRLSCAASGGYTFTNYGMNNWRQAPGKGLEWVGWINTYTGEPTYAADEFKRRVFTISLDNSKSTVYLQMNNSLRAEDTAVYCAKYPHYGSSH  
WYFDVWQGGTLVTVSS

SEQ ID NO : 67  
EVQLVQSGGGVVQPGGSLRLSCAASGGYTFTNYGMNNWRQAPGKGLEWVGWINTYTGEPTYAADEFKRRVTFSLNTSKSTAYLQLNSLRAEDTAVYCAKYPHYGSSH  
WYFDVWQGGTLVTVSS

SEQ ID NO : 68  
EVQLVQSGGGVVQPGGSLRLSCAASGGYTFTNYGMNNWRQAPGKGLEWVGWINTYTGEPTYAADEFKRRVTFSLNTSKSTAYLQLNSLRAEDTAVYCAKYPHYGSSH  
WYFDVWQGGTLVTVSS

SEQ ID NO : 69  
EVQLVQSGGGVVQPGGSLRLSCAASGGYTFTNYGMNNWRQAPGKGLEWVGWINTYTGEPTYAADEFKRRVTFSLDTSKNTAYLQLNSLRAEDTAVYCAKYPHYGSSH  
WYFDVWQGGTLVTVSS

SEQ ID NO : 70  
EVQLVQSGGGVVQPGGSLRLSCAASGGYTFTNYGMNNWRQAPGKGLEWVGWINTYTGEPTYAADEFKRRVTFSLDTSKNTAYLQLNSLRAEDTAVYCAKYPHYGSSH  
WYFDVWQGGTLVTVSS

SEQ ID NO : 71  
EVQLVQSGGGVVQPGGSLRLTCAASGGYTFTNYGMNNWRQAPGKGLEWVGWINTYTGEPTYAADEFKRRVTFSLDNNSKSTAYLQLNSLRAEDTAVYCAKYPHYGSSH  
WYFDVWQGGTLVTVSS

SEQ ID NO : 72  
EVQLVQSGGGVVQPGGSLRLTCAVSGGYTFTNYGMNNWRQAPGKGLEWVGWINTYTGEPTYAADEFKRRVFTISRDTSKNQAYLQMNNSLRAEDTAVYCAKYPHYGSSH  
WYFDVWQGGTLVTVSS

No changes

Figure 1D-cont.

SEQ ID NO : 73  
EVQLVQSGGGVQVQPGGSLRLSCAASGYTFTNYGMNNIRQAPGKGLEWVGWINTYGEPTYAADEFKRRVTFSLDTSKSTAYLQIQLNSLRAEDTAVYYCAKYPHYYGSSH  
WYFDVWQGQGTILVTVSS

SEQ ID NO : 74  
EVQLVQSGGGVQVQPGGSLRLSCAASGYTFTNYGMNNIRQAPGKGLEWVGWINTYGEPTYAADEFKRRVTFSLDTSKSTAYLQIQLNSLRAEDTAVYYCAKYPHYYGSSH  
WYFDVWQGQGTILVTVSS

SEQ ID NO : 75  
EVQLVQSGGGVQVQPGGSLRLSCAASGYTFTNYGMNNIRQAPGKGLEWVGWINTYGEPTYAADEFKRRVTFSLDTSKSTAYLQIQLNSLRAEDTAVYYCAKYPHYYGSSH  
WYFDVWQGQGTILVTVSS

SEQ ID NO : 76  
EVQLVQSGGGVQVQPGGSLRLSCAASGYTFTNYGMNNIRQAPGKGLEWVGWINTYGEPTYAADEFKRRVTFSLDTSKSTAYLQIQLNSLRAEDTAVYYCARRYCAKYPHYYGSSH  
WYFDVWQGQGTILVTVSS

SEQ ID NO : 77  
QVQLVQSGGGVQVQPGGSLRLSCAASGYTFTNYGMNNIRQAPGKGLEWVGWINTYGEPTYAADEFKRRVTFSLDTSKSKAYLQIQLNSLRAEDTAVYYCARRYCAKYPHYYGSSH  
WYFDVWQGQGTILVTVSS

SEQ ID NO : 78  
QVQLVQSGGGVQVQPGGSLRLSCAASGYTFTNYGMNNIRQAPGKGLEWVGWINTYGEPTYAADEFKRRVTFSLDTSKSKAYLQIQLNSLRAEDTAVYYCAKYPHYYGSSH  
WYFDVWQGQGTILVTVSS

SEQ ID NO : 79  
QVQLVQSGGGVQVQPGGSLRLSCAASGYTFTNYGMNNIRQAPGKGLEWVGWINTYGEPTYAADEFKRRVTFSLDTSKNTAYLQIQLNSLRAEDTAVYYCAKYPHYYGSSH  
WYFDVWQGQGTILVTVSS

SEQ ID NO : 80  
QVQLVQSGGGVQVQPGGSLRLSCAASGYTFTNYGMNNIRQAPGKGLEWVGWINTYGEPTYAADEFKRRVTFSLDTSKNTAYLQIQLNSLRAEDTAVYYCAKYPHYYGSSH  
WYFDVWQGQGTILVTVSS

SEQ ID NO : 81  
QVQLVQSGGGVQVQPGGSLRLSCAASGYTFTNYGMNNIRQAPGKGLEWVGWINTYGEPTYAADEFKRRVTFSLDTSKSQAYLQIQLNSLRAEDTAVYYCAKYPHYYGSSH  
WYFDVWQGQGTILVTVSS

SEQ ID NO : 82  
QVQLVQSGGGVQVQPGGSLRLSCAASGYTFTNYGMNNIRQAPGKGLEWVGWINTYGEPTYAADEFKRRVTFSLDTSKSTAYLQIQLNSLRAEDTAVYYCAKYPHYYGSSH  
WYFDVWQGQGTILVTVSS



Figure 1D-cont.

SEQ ID NO : 83  
 QVOLVQSGGGVVQPGGSSLRLTCAASGGYTFPTNYGMNMVRQAPGKGLEMWVGWINTYTGEPTYAADFKRRTFISLDTSKSQLQMNLSLRAEDTAVYCAKYPHYGGSSH  
 WYFDVWGGTILVTVSS

SEQ ID NO : 84  
 QVQLVQSGGGVVQPGGTLRLTCAASGGYTFPTNYGMNMWIROQAPGKGLEMWVGWINTYTGEPTYAADFKRRTFISLDTSKSQLQMNLSLRAEDTAVYCAKYPHYGGSSH  
 WYFDVWGGTILVTVSS

SEQ ID NO : 85  
 EVQLVQSGGGVVQPGGSSLRLSCAASGGYTFTHYGLNWLROQAPGKGPMEWVGWINTYTGETTYADEFKRRVTFSLDTSKSTAYLQLNLSLRAEDTAVYCAKPYYYGRSH  
 YFDVWGGTILVTVSS

SEQ ID NO : 86  
 EVQLVQSGGGVVQPGGSSLRLSCAASGGFNFTHYGINWIRQAPGKGPMEWVGWINTNNGEPTYAQDFKRRVTFSLDTSKSTAYLQLNLSLRAEDTAVYCAKPYYYGRSH  
 WYFDVWGGTILVTVSS

SEQ ID NO : 87  
 EVQLVQSGGGVVQPGGSSLRLSCAASGGYDFAHYGLNWIROQAPGKGLEMWVGWINTYTGESTTYVPEFKRRVTFSLDTSKSTAYLQLNLSLRAEDTAVYCAKPYYYGRSH  
 WYFDVWGGTILVTVSS

SEQ ID NO : 88  
 EVQLVQSGGGVVQPGGSSLRLSCAASGGYDFAHYGLNWIROQAPGKGLEMWVGWINTYTGETTYAHDFFKRRVTFSLDTSKSTAYLQLNLSLRAEDTAVYCAKPYYYGRSH  
 WYFDVWGGTILVTVSS

SEQ ID NO : 89  
 EVQLVQSGGGVVQPGGSSLRLSCAASGGYDFDHFGLNWIROQAPGKGLEMWVGWINTYTGEPTYVDEFKRRVTFSLDTSKSTAYLQLNLSLRAEDTAVYCAKPYYYGRSH  
 WYFDVWGGTILVTVSS

SEQ ID NO : 90  
 EVQLVQSGGGVVQPGGSSLRLSCAASGGYDFDHFGLNWIROQAPGKGPMEWVGWINTYTGEPTYVDEFKRRVTFSLDTSKSTAYLQLNLSLRAEDTAVYCAKPYYYGRSH  
 WYFDVWGGTILVTVSS

SEQ ID NO : 91  
 EVQLVQSGGGVVQPGGSSLRLSCAASGYDFNNYGMNMWIROQAPGKGPMEWVGWINTYNGEPTYADFFKRRVTFSLDTSKSTAYLQLNLSLRAEDTAVYCAKPYYYGRSH  
 WYFDVWGGTILVTVSS

Corrected typographical error to change "SEQ 90" to "SEQ 10" to "SEQ 10 No : 90"

Figure 1D-cont.

SEQ ID NO: 92  
EVQLVQSGGGVVQPGGSLRLSCAASGYDFSHFGINWIROQAPGKGLEWVGWINTYGETTYAHDFKRRTFSLDTSKSTAYLQNSLRAEDTAVYCAKPYYYGRSH  
WYFDVWQGQTLVTVSS

SEQ ID NO: 93  
EVQLVQSGGGVVQPGGSLRLSCAASGYDFSHFGINWIROQAPGKGLEWVGWINTYGETTYAHDFKRRTFSLDTSKSTAYLQNSLRAEDTAVYCAKPYYYGRSH  
WYFDVWQGQTLVTVSS

SEQ ID NO: 94  
EVQLVQSGGGVVQPGGSLRLSCAASGYDFSNYGLNWMVRQAPGKGPMEWVGWINTYGEPTYAEEFTRVTFSLDTSKSTAYLQNSLRAEDTAVYCAKPYYYGRSH  
WYFDVWQGQTLVTVSS

SEQ ID NO: 95  
EVQLVQSGGGVVQPGGSLRLSCAASGYDFTHYGLNWIROQAPGKGPMEWVGWINTYGETTYAHEFTRVTFSLDTSKSTAYLQNSLRAEDTAVYCAKPYYYGRSH  
WYFDVWQGQTLVTVSS

SEQ ID NO: 96  
EVQLVQSGGGVVQPGGSLRLSCAASGYNFYHYGVNWMVRQAPGKGPMEWVGWINTYGETTYAQEFKRTFSLDTSKSTAYLQNSLRAEDTAVYCAKPYYYGRSH  
WYFDVWQGQTLVTVSS

SEQ ID NO: 97  
EVQLVQSGGGVVQPGGSLRLSCAASGYSFDHYGLNWMVRQAPGKGLEWVGWINTYGEPTYADEFTRVTFSLDTSKSTAYLQNSLRAEDTAVYCAKPYYYGRSH  
WYFDVWQGQTLVTVSS

SEQ ID NO: 98  
EVQLVQSGGGVVQPGGSLRLSCAASGYSFDTNYGMNWIROQAPGKGLEWVGWINTYGEPTYAADFTRVTFSLDTSKSTAYLQNSLRAEDTAVYCAKPYYYGRSH  
WYFDVWQGQTLVTVSS

SEQ ID NO: 99  
EVQLVQSGGGVVQPGGSLRLSCAASGYTFTNYGMNWIROQAPGKGLEWVGWINTYGEPTYAADFKRRTFSLDTSKSTAYLQNSLRAEDTAVYCAKPYYYGRSH  
WYFDVWQGQTLVTVSS

SEQ ID NO: 100  
EVQLVQSGGGVVQPGGSLRLSCAASGYTFTNYGMNWIROQAPGKGLEWVGWINTYGEPTYAADFKRRTFSLDTSKSTAYLQNSLRAEDTAVYCAKPYYYGRSH  
WYFDVWQGQTLVTVSS

SEQ ID NO: 101  
EVQLVQSGGGVVQPGGSLRLSCAASGYTFTNYGMNWMVRQAPGKGLEWVGWINTYGEPTYAADFKRRTFSLDTSKSTAYLQMNNSLRAEDTAVYCAKPYYYGRSH  
WYFDVWQGQTLVTVSS

No Changes

ANNOTATED SHEET

USSN 10/723,434

SHEET 6/14

FIGURE 1D

Figure 1D-cont.

SEQ ID NO :102  
EVQLVQSGGGVVQPGGSLRLSCAASGGYTFNTYGMNNVRQAPGKGLEWVGWINTYTGEPYAADFKRRTFSLDTSKSTAYLQMNLSLRAEDTAVYCAKYPYYGRSH  
WYFDVWQGQGTLLVTVSS

SEQ ID NO :103  
EVQLVSGGGLVQPGGSLRLSCAASGGYTFNTYGMNNVRQAPGKGLEWVGWINTYTGEPYAADFKRRTFSLDTSKSTAYLQMNLSLRAEDTAVYCAKYPYYGTSH  
WYFDVWQGQGTLLVTVSS

SEQ ID NO :104  
EVQLVSGGGLVQPGGSLRLSCAASGGYTFNTYGMNNVRQAPGKGLEWVGWINTYTGEPYAADFKRRTFSLDTSKSTAYLQMNLSLRAEDTAVYCAKYPHYGRSH  
WYFDVWQGQGTLLVTVSS

SEQ ID NO :105  
EVOLVSGGGLVQPGGSLRLSCAASGGYTFNTYGMNNVRQAPGKGLEWVGWINTYTGEPYAADFKRRTFSLDTSKSTAYLQMNLSLRAEDTAVYCAKYPYYGRSH  
WYFDVWQGQGTLLVTVSS

SEQ ID NO :106  
EVQLVQSGGGVVQPGGSLRLSCAASGGYDFTHFLGLNWIROQAPGKGPWEVGWINTYTGEPYAADFKRRTFSLDTSKSTAYLQLNLSLRAEDTAVYCAKYPYYGRSH  
WYFDVWQGQGTLLVTVSS

SEQ ID NO :107  
EVQLVQSGGGVVQPGGSLRLSCAASGGYDLSHYGLNWIROQAPGKGPEVGWINTYTGEPYADFTTRVTFSLDTSKSTAYLQLNLSLRAEDTAVYCAKYPYYGRSH  
WYFDVWQGQGTLLVTVSS

SEQ ID NO :108  
EVQLVQSGGGVVQPGGSLRLSCAASGGYNFSHFLGLNWLROQAPGKGLEWVGWINTYGETTYAPDFKRVTFSLDTSKSTAYLQLNLSLRAEDTAVYCAKYPYYGRSH  
WYFDVWQGQGTLLVTVSS

SEQ ID NO :109  
EVQLVQSGGGVVQPGGSLRLSCAASGGYNFSHFLGLNWLROQAPGKGPEVGWINTYTGEPYAPEFKRRTFSLDTSKSTAYLQLNLSLRAEDTAVYCAKYPYYGRSH  
WYFDVWQGQGTLLVTVSS

SEQ ID NO :110  
EVQLVQSGGGVVQPGGSLRLSCAASGGYDFTHFLGLNWLROQAPGKGLEWVGWINTYGETTYAHEFKRRTFSLDTSKSTAYLQLNLSLRAEDTAVYCAKYPYYGRSH  
WYFDVWQGQGTLLVTVSS

No Changes

ANNOTATED SHEET

USSN 10/723,434

SHEET 7/14

FIGURE 1D

Figure 1D-cont.

SEQ ID NO:283  
EIQLVQSGPELKQPGETVRISCKASGGTFTNYGMNWWVKQAPGKGLKWMGWI**INTYTGEPTYAADF**KRRTFSLETSASTAYLQI**SNL**KNDDTATYFCAKYPHYGSSH  
WYFDVWAGTIVTVSS

SEQ ID NO:285  
EVQLVESGGGLVQPGGSLRLSCAASGGTFTNYGMNWWVRQAPGKGLEWVG**WINTYTGEPTYAADF**KRRTFSLDTSKSTAYLQ**MNSL**RAEDTAVYYCAHSRHYGSSP  
WYFDVWAGTIVTVSS

SEQ ID NO:286  
EVQLVESGGGLVQPGGSLRLSCAASGGTFTNYGMNWWVRQAPGKGLEWVG**WINTYTGEPTYAADF**KRRTFSLDTSKSTAYLQ**MNSL**RAEDTAVYYCAKYGYYGSSH  
WYFDVWAGTIVTVSS

SEQ ID NO:287  
EVQLVESGGGLVQPGGSLRLSCAASGGTFTNYGMNWWVRQAPGKGLEWVG**WINTYTGEPTYAADF**KRRTFSLDTSKSTAYLQ**MNSL**RAEDTAVYYCAKYPHYGASH  
WYFDVWAGTIVTVSS

SEQ ID NO:288  
EVQLVESGGGLVQPGGSLRLSCAASGGTFTNYGMNWWVRQAPGKGLEWVG**WINTYTGEPTYAADF**KRRTFSLDTSKSTAYLQ**MNSL**RAEDTAVYYCAKYPHYGGCH  
WYFDVWAGTIVTVSS

SEQ ID NO:289  
EVQLVESGGGLVQPGGSLRLSCAASGGTFTNYGMNWWVRQAPGKGLEWVG**WINTYTGEPTYAADF**KRRTFSLDTSKSTAYLQ**MNSL**RAEDTAVYYCAKYPHYGGSH  
WYFDVWAGTIVTVSS

SEQ ID NO:290  
EVQLVESGGGLVQPGGSLRLSCAASGGTFTNYGMNWWVRQAPGKGLEWVG**WINTYTGEPTYAADF**KRRTFSLDTSKSTAYLQ**MNSL**RAEDTAVYYCAKYPHYGRSH  
WYFDVWAGTIVTVSS

SEQ ID NO:291  
EVQLVESGGGLVQPGGSLRLSCAASGGTFTNYGMNWWVRQAPGKGLEWVG**WINTYTGEPTYAADF**KRRTFSLDTSKSTAYLQ**MNSL**RAEDTAVYYCAKYPHYGRS  
WYFDVWAGTIVTVSS

SEQ ID NO:293  
EVQLVESGGGLVQPGGSLRLSCAASGGTFTNYGMNWWVRQAPGKGLEWVG**WINTYTGEPTYAADF**KRRTFSLDTSKSTAYLQ**MNSL**RAEDTAVYYCAKYPHYGRS  
WYLDVWAGTIVTVSS

*No. Changes*

Figure 1D-cont.

SEQ ID NO: 294  
 EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWRQAPGKGLEWVGWINTYTGEPTYAADFKRRTFSLDTSKSTAYLQMNLSRAEDTAVYCAKYPHYYSRTC  
 QYFDVWQGQTLVTVSS

SEQ ID NO: 295  
 EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWRQAPGKGLEWVGWINTYTGEPTYAADFKRRTFSLDTSKSTAYLQMNLSRAEDTAVYCAKYPHYSSSH  
 WYFDVWQGQTLVTVSS

SEQ ID NO: 296  
 EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWRQAPGKGLEWVGWINTYTGEPTYAADFKRRTFSLDTSKSTAYLQMNLSRAEDTAVYCAKYPFYGSSH  
 WYFDVWQGQTLVTVSS

SEQ ID NO: 297  
 EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWRQAPGKGLEWVGWINTYTGEPTYAADFKRRTFSLDTSKSTAYLQMNLSRAEDTAVYCAKYPYYHGSSH  
 WYFDVWQGQTLVTVSS

SEQ ID NO: 298  
 EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWRQAPGKGLEWVGWINTYTGEPTYAADFKRRTFSLDTSKSTAYLQMNLSRAEDTAVYCAKPYYNSTSH  
 WYFDVWQGQTLVTVSS

SEQ ID NO: 299  
 EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWRQAPGKGLEWVGWINTYTGEPTYAADFKRRTFSLDTSKSTAYLQMNLSRAEDTAVYCAKPYYSGTSH  
 WYFDVWQGQTLVTVSS

SEQ ID NO: 300  
 EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWRQAPGKGLEWVGWINTYTGEPTYAADFKRRTFSLDTSKSTAYLQMNLSRAEDTAVYCAKPYYYGRSH  
 WYFDVWQGQTLVTVSS

SEQ ID NO: 301  
 EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWRQAPGKGLEWVGWINTYTGEPTYAADFKRRTFSLDTSKSTAYLQMNLSRAEDTAVYCAKPYYYGRSH  
 WYFDVWQGQTLVTVSS

SEQ ID NO: 302  
 EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWRQAPGKGLEWVGWINTYTGEPTYAADFKRRTFSLDTSKSTAYLQMNLSRAEDTAVYCAKPYYYGSSH  
 WYFDVWQGQTLVTVSS

No. Chars

Figure 1D-cont.

SEQ ID NO : 304  
EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWRQAPGKGLEWVGWINTYGEPTYAADFKRRTFSLDTSKSTAYLQMNSLRAEDTAVYCAKPYYYGSSH  
WYFDVWGGTILVTVSS

SEQ ID NO : 305  
EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWRQAPGKGLEWVGWINTYGEPTYAADFKRRTFSLDTSKSTAYLQMNSLRAEDTAVYCAKPYYYSTSH  
WYFDVWGGTILVTVSS

SEQ ID NO : 306  
EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWRQAPGKGLEWVGWINTYGEPTYAADFKRRTFSLDTSKSTAYLQMNSLRAEDTAVYCAKYRDFNGSSH  
WYFDVWGGTILVTVSS

SEQ ID NO : 307  
EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWRQAPGKGLEWVGWINTYGEPTYAADFKRRTFSLDTSKSTAYLQMNSLRAEDTAVYCAKSYYYGSSH  
WYFDVWGGTILVTVSS

SEQ ID NO : 308  
EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWRQAPGKGLEWVGWINTYGEPTYAADFKRRTFSLDTSKSTAYLQMNSLRAEDTAVYCARARHYYGSSH  
CYFDLWGGTILVTVSS

SEQ ID NO : 309  
EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWRQAPGKGLEWVGWINTYGEPTYAADFKRRTFSLDTSKSTAYLQMNSLRAEDTAVYCARDSHYYGSSH  
QYFDLWGGTILVTVSS

SEQ ID NO : 310  
EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWRQAPGKGLEWVGWINTYGEPTYAADFKRRTFSLDTSKSTAYLQMNSLRAEDTAVYCAKPYYYGTSW  
WYFDVWGGTILVTVSS

N. Changes,

Figure 1D-cont.

**Amino Acid Sequences of  $V_h/CDR1$  of Selected Anti-VEGF Antibodies**

SEQ ID NO:111	GYDFFTNYGMN
SEQ ID NO:112	GYTFINYGMN
SEQ ID NO:113	GYSLDHYGMN
SEQ ID NO:114	GYALDHFGLN
SEQ ID NO:115	GYDFNYNGIN
SEQ ID NO:116	GYTFINYGMN
SEQ ID NO:117	GYSFDHYGLN
SEQ ID NO:118	GYDFSNYGLN
SEQ ID NO:119	GYDFSHFGIN
SEQ ID NO:120	GYDFAHYGVN
SEQ ID NO:121	GYDFDHFGIN
SEQ ID NO:122	GYDFNNYGMN
SEQ ID NO:123	GYDFAASFGIN
SEQ ID NO:124	GFNFTHYGIN
SEQ ID NO:125	GYDFAHYGLN
SEQ ID NO:126	GYNFYHYGVN
SEQ ID NO:127	GYDFTHYGLN
SEQ ID NO:128	GYNFYSYGLN
SEQ ID NO:129	GYDFSHFGIN
SEQ ID NO:130	GYTFTHYGLN
SEQ ID NO:131	GYDFTFHGLN
SEQ ID NO:132	GYDLSHYGLN
SEQ ID NO:133	GYNFSHFGIN
SEQ ID NO:134	GYNFSHFGLN
SEQ ID NO:135	GYDFTFHGLN

No. Chars

Figure 1D-cont.

**Amino Acid Sequences of V<sub>H</sub>/CDR2 of Selected Anti-VEGF Antibodies**

SEQ ID NO:136	WINTYTGEPTYAHEFTR
SEQ ID NO:137	WINTYTGEPTYAADFTR
SEQ ID NO:138	WINTYTGEPTYADEFTR
SEQ ID NO:139	WINTYTGEPTYAEEFTR
SEQ ID NO:140	WINTYTGETTYVPEFKR
SEQ ID NO:141	WINTYTGETTYAHDFFKR
SEQ ID NO:142	WINTYTGEPTYVDEFFKR
SEQ ID NO:143	WINTYNGEPTYAPDFKR
SEQ ID NO:144	WINTYTGETSYAQDFKR
SEQ ID NO:145	WINTNNGEPTYAQDFKR
SEQ ID NO:146	WVNNTYGETSYVPEFKR
SEQ ID NO:147	WVNNTYGETTYAQEFKR
SEQ ID NO:148	WINTYTGETTYAHEFTR
SEQ ID NO:149	WINTYTGEPTYAQEFKR
SEQ ID NO:150	WINTYTGETTYAHDFFKR
SEQ ID NO:151	WVNNTYGETTYADEFKR
SEQ ID NO:152	WINTYTGEPTYAQDFKR
SEQ ID NO:153	WINTYTGEPTYAPDFTR
SEQ ID NO:154	WVNNTYGETTYAPDFKR
SEQ ID NO:155	WINTYTGEPTYAPEFKR
SEQ ID NO:156	WVNNTYGETTYAHEFKR

No Change

Figure 1D-cont.

**Amino Acid Sequences of V<sub>H</sub>/CDR3 of Selected Anti-VEGF Antibodies**

SEQ ID NO:311	CAHSRHYGGSSPQYFDV
SEQ ID NO:312	CAKYGYGGSSHWMYFDV
SEQ ID NO:313	CAKYPHYGGASHWMYFDV
SEQ ID NO:314	CAKYPHYGGCHWMYFDV
SEQ ID NO:315	CAKYPHYGGSSHWMYFDV
SEQ ID NO:316	CAKYPHYGGYNQYFDV
SEQ ID NO:317	CAKYPHYGGRSHWMYFDV
SEQ ID NO:318	CAKYPHYGRSQWYLDV
SEQ ID NO:319	CAKYPHYSSRTQCQYFDV
SEQ ID NO:320	CAKYPHYSSSHWMYFDV
SEQ ID NO:321	CAKYPYFYGSSHWMYFDV
SEQ ID NO:322	CAKYPPYHGSSSHWMYFDV
SEQ ID NO:323	CAKYPPYNGSSHWMYFDV
SEQ ID NO:324	CAKYPPYNSTSHWMYFDV
SEQ ID NO:325	CAKYPPYSGTSHWMYFDV
SEQ ID NO:326	CAKYPPYSGTSHWMYFDY
SEQ ID NO:327	CAKYPPYYGRSHWMYFDV
SEQ ID NO:328	CAKYPPYYGSSSHWMYFDV
SEQ ID NO:329	CAKYPPYYGSSSSWYFDV
SEQ ID NO:330	CAKYPPYYSTSHWMYFDV
SEQ ID NO:331	CAKYRDFNGSSSHWMYFDV
SEQ ID NO:332	CAKYSYYGSSSHWMYFDV
SEQ ID NO:333	CARARHYGGSSHCVYFDL
SEQ ID NO:334	CARDSHHYGGSSHQYFDSL
SEQ ID NO:335	CAKYPHYGGTSHWMYFDV
SEQ ID NO:336	CAKYPHYGGSSHWMYFDV
SEQ ID NO:337	CAKYPPYYGTSHWMYFDV

No Changes

Figure 1D-cont.

Amino Acid Sequences of V<sub>h</sub>/FRs of Selected Anti-VEGF Antibodies

SEQ ID NOS <u>157</u> and <u>402-404</u> EVQLVQSGGGVVQPGGSLRLSCAAS/CDR1/WIRQAPGKGLEWVG/CDR2/RFTFSLDTSKSTAYLQMNSLRAEDTAVYYCA/CDR3/WGQGTLVTVSS	<b>Deleted:</b> :
SEQ ID NOS <u>158</u> , <u>402</u> , <u>405</u> and <u>404</u> EVQLVQSGGGVVQPGGSLRLSCAAS/CDR1/WIRQAPGKGLEWVG/CDR2/RFTFSLDTSKNTAYLQMNSLRAEDTAVYYCA/CDR3/WGQGTLVTVSS	<b>Deleted:</b> :
SEQ ID NOS <u>159</u> , <u>406-407</u> and <u>404</u> EVQLVQSGGGVVQPGGSLRLSCAAS/CDR1/WIRQAPGKGLEWVG/CDR2/RFTFSLDTSKNTAYLQMNSLRAEDTAVYYCA/CDR3/WGQGTLVTVSS	<b>Deleted:</b> :
SEQ ID NOS <u>160</u> , <u>406</u> , <u>408</u> and <u>404</u> EVQLVQSGGGVVQPGGSLRLSCAAS/CDR1/WIRQAPGKGLEWVG/CDR2/RFTFSLDTSKNTAYLQMNSLRAEDTAVYYCA/CDR3/WGQGTLVTVSS	<b>Deleted:</b> :
SEQ ID NOS <u>161</u> , <u>406</u> , <u>409</u> and <u>404</u> EVQLVQSGGGVVQPGGSLRLSCAAS/CDR1/WIRQAPGKGLEWVG/CDR2/RFTFSLDTSKNTAYLQMNSLRAEDTAVYYCA/CDR3/WGQGTLVTVSS	<b>Deleted:</b> :
SEQ ID NOS <u>162</u> , <u>402</u> , <u>410</u> and <u>404</u> EVQLVQSGGGVVQPGGSLRLSCAAS/CDR1/WIRQAPGKGLEWVG/CDR2/RFTFSLDTSKNTAYLQMNSLRAEDTAVYYCA/CDR3/WGQGTLVTVSS	<b>Deleted:</b> :
SEQ ID NOS <u>163</u> , <u>402</u> , <u>411</u> and <u>404</u> EVQLVQSGGGVVQPGGSLRLSCAAS/CDR1/WIRQAPGKGLEWVG/CDR2/RFTFSLDTSKNTAYLQMNSLRAEDTAVYYCA/CDR3/WGQGTLVTVSS	<b>Deleted:</b> :
SEQ ID NOS <u>270</u> , <u>406</u> and <u>412-413</u> EVQLVQSGGGVVQPGGSLRLSCAAS/CDR1/WIRQAPGKGLEWVG/CDR2/RFTFSLDTSKNTAYLQMNSLRAEDTAVYYCA/CDR3/WAQGTLVTVSS	<b>Deleted:</b> :
SEQ ID NOS <u>271</u> , <u>406</u> , <u>414</u> and <u>404</u> EVQLVQSGGGVVQPGGSLRLSCAAS/CDR1/WIRQAPGKGLEWVG/CDR2/RFTFSLDTSKNTAYLQMNSLRAEDTAVYYCA/CDR3/WGQGTLVTVSS	<b>Deleted:</b> :
SEQ ID NOS <u>272</u> , <u>406</u> , <u>409</u> and <u>404</u> EVQLVQSGGGVVQPGGSLRLSCAAS/CDR1/WIRQAPGKGLEWVG/CDR2/RFTFSLDTSKNTAYLQMNSLRAEDTAVYYCA/CDR3/WGQGTLVTVSS	<b>Deleted:</b> :
SEQ ID NOS <u>273</u> , <u>406</u> , <u>405</u> and <u>404</u> EVQLVQSGGGVVQPGGSLRLSCAAS/CDR1/WIRQAPGKGLEWVG/CDR2/RFTFSLDTSKNTAYLQMNSLRAEDTAVYYCA/CDR3/WGQGTLVTVSS	<b>Deleted:</b> :
SEQ ID NOS <u>274</u> , <u>406</u> , <u>409</u> and <u>404</u> EVQLVQSGGGVVQPGGSLRLSCAAS/CDR1/WIRQAPGKGLEWVG/CDR2/RFTFSLDTSKNTAYLQMNSLRAEDTAVYYCA/CDR3/WGQGTLVTVSS	<b>Deleted:</b> :

The Sequence Identifiers Listed Above in Blue Text were added to each of the Sequence descriptions and '!'s were removed after the term "SEQ 10 NOS."

ANNOTATED SHEET  
USSN 10/723,434  
SHEET 14/14  
FIGURE 1D

Figure 1D-cont.

SEQ ID NQS 275, 406, 411 and 404  
EVQLVQSGGGVVQPGGTLRLTCAAS/CDR1/WIRQAPGKGLEWVG/CDR2/RVTFSLDTSKSTAYLQMNSLRAEDTAVYYCA/CDR3/WGQGTLVTVSS  
Deleted: : [REDACTED]

SEQ ID NQS 276, 402, 415 and 404  
EVQLVQSGGGVVQPGGTLRLTCAAS/CDR1/WIRQAPGKGLEWVG/CDR2/RVTISLDTSKSTAYLQMNSLRAEDTAVYYCA/CDR3/WGQGTLVTVSS  
Deleted: : [REDACTED]

SEQ ID NQS 277, 406, 416 and 404  
QVQLVESGGGLVQPGGSLRLTCAAS/CDR1/WIRQAPGKGLEWVG/CDR2/RFTFSLDTSKSKAYLQNSLRAEDTAVYYCA/CDR3/WGQGTLVTVSS  
Deleted: : [REDACTED]

SEQ ID NQS 278, 406, 417 and 404  
QVQLVQSGGGVVQPGGSLRLSCAAS/CDR1/WIRQAPGKGLEWVG/CDR2/RVTISLDTSKNTAYLQNSLRAEDTAVYYCA/CDR3/WGQGTLVTVSS  
Deleted: : [REDACTED]

SEQ ID NQS 279, 402, 418 and 404  
QVQLVQSGGGVVQPGGSLRLSCAAS/CDR1/WIRQAPGKGLEWVG/CDR2/RFTISLDTSKNTAYLQNSLRAEDTAVYYCA/CDR3/WGQGTLVTVSS  
Deleted: : [REDACTED]

SEQ ID NQS 280, 406, 419 and 404  
QVQLVQSGGGVVQPGGSLRLTCAAS/CDR1/WIRQAPGKGLEWVG/CDR2/RVTISLDTSKSOAYLQMNSLRAEDTAVYYCA/CDR3/WGQGTLVTVSS  
Deleted: : [REDACTED]

SEQ ID NQS 281, 406, 420 and 404  
QVQLVQSGGGVVQPGGSLRLTCAAS/CDR1/WIRQAPGKGLEWVG/CDR2/RVTISLDTSKSTAYLQNSLRAEDTAVYYCA/CDR3/WGQGTLVTVSS  
Deleted: : [REDACTED]

SEQ ID NQS 282, 406, 414 and 404  
QVQLVQSGGGVVQPGGTLRLTCAAS/CDR1/WIRQAPGKGLEWVG/CDR2/RFTFSLDTSKNTAYLQMNSLRAEDTAVYYCA/CDR3/WGQGTLVTVSS  
Deleted: : [REDACTED]

[ Some Annotations as for Sheet 13] The Sequence Identifiers Listed Above in Blue Text were added to each of the sequence descriptions and " " was removed after the term "SEQ ID Nos."